Valuation
- Market cap
- 35,797,000
- Revenue TTM
- $10,000
- Net income TTM
- $-48,070,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- -480,700.01%
- Debt to equity
- 0.00
Trading
- Volume
- 13,500
- Avg volume
- 6,460
- Day's range
- $0.60 – $0.62
- Shares out
- 59,305,000
- Stochastic %K
- 79%
- Beta
- 1.75
- Analysts
- —
- Price target
- $4.00
Company profile
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers in Israel and the United States. The company is developing AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit...
Show more
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers in Israel and the United States. The company is developing AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. The company was incorporated in 1987 and is based in Monmouth Junction, New Jersey.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 609 452 9813
- Website
- https://www.ayalapharma.com
- Address
- 9 Deer Park Drive, Suite K-1, Monmouth Junction, United States
Latest news
No headlines yet.
